Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18287861 | 0.84 | CDK1 (0.34) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL22327308 | 0.79 | CDK1 (0.33) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL12206794 | 0.75 | ADORA2A (0.36) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL24538994 | 0.74 | TET2 (0.40) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL10137844 | 0.74 | ADORA2A (0.38) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL10137834 | 0.74 | CDK1 (0.34) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL23615800 | 0.73 | TBK1 (0.35) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL8840859 | 0.72 | — | — | |
| SCHEMBL25753271 | 0.72 | TLR8 (0.31) | — | |
| SCHEMBL22815034 | 0.71 | CDK1 (0.33) | CDK1CCNB1CCNE1CDK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172896-A1 | EVOLUTION OF BIOACTIVE SEQUENCE-DEFINED SYNTHETIC POLYMERS USING DNA-TEMPLATED POLYMERIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172896-A1 | EVOLUTION OF BIOACTIVE SEQUENCE-DEFINED SYNTHETIC POLYMERS USING DNA-TEMPLATED POLYMERIZATION | PCSK9, IL6, PCSK6 | CDK1 2159/4885CCNB1 2649/4885CCNE1 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.